Note: The London Stock Exchange recently published guidance for AIM companies in relation to the September 2018 Corporate Governance Changes. The guidance states that it is acceptable for the AIM Rule 26 website compliance statement to incorporate by reference (for example disclosures that are provided in a clearly delineated corporate governance section of the annual report) provided that the material is freely available and the statement clearly indicates where interested parties can read or obtain a copy of that material (for example, the relevant pages or section of the annual report or the URL for the relevant web page). We have applied this approach (i.e. incorporation by reference to the Company's annual report) in respect of certain sections in this statement. Click here to access the guidance.
Hutchison China MediTech Limited ("Company")
The Company strives to attain and maintain high standards of corporate governance best suited to the needs and interests of the Company and its subsidiaries (the "Group") as it believes that effective corporate governance practices are fundamental to safeguarding shareholder interests and enhancing shareholder value. Accordingly, the Company has adopted corporate governance principles that emphasise a quality board of Directors (the "Board"), effective internal controls, stringent disclosure practices, transparency and accountability. It is, in addition, committed to continuously improving these practices and inculcating an ethical corporate culture.
The Company has applied the principles and provisions of the UK Corporate Governance Code published by the Financial Reporting Council on 17 June 2016 (the "Code"). This statement sets out in broad terms how we comply at this point in time. We will provide updates as circumstances change. A full version of the Code is available from the Financial Reporting Council website at www.frc.org.uk.
It is noted that a revised UK Corporate Governance Code was published on 15 July 2018 which applies to accounting periods beginning on or after 1 January 2019. The Company expects to report against this revised code in 2019.
The Company's explanations for departures from certain provisions of the Code for the year ended 31 December 2017 are set out below:
The information in this statement was last reviewed on 27 September 2018. This statement incorporates by reference the disclosures set out in the Company's Corporate Governance Report found on pages 49 to 60 of the Company's 2017 Annual Report. This can be accessed here.
 Inclusive of Dr Weiguo Su who was appointed on 27 March 2017.
 Exclusive of Mr Shiguro Endo who resigned on 1 February 2017.
 Inclusive of Mr Paul Carter and Dr Karen Ferrante who were both appointed on 1 February 2017, Mr Graeme Jack who was appointed on 1 March 2017 and Professor Tony Mok who was appointed on 12 October 2017; and exclusive of Professor Christopher Huang and Mr Christopher Nash who both resigned on 1 February 2017, and Mr Michael Howell who resigned on 1 March 2017.